NEWS & EVENTS

Investor Forum: Wednesday 29th November

We will be hosting our next Investor Forum at Hudson Sandler on the evening of Wednesday 29th November 2017 and …

READ MORE

Impax Asset Management webinar: Monday 23rd October, 12:30pm

The management of Impax Asset Management (AIM:IPX) will be hosting a webinar regarding the details of the acquisition plans for …

READ MORE

Deltex Medical Webinar Tuesday 12th September 12:45pm

The management of Deltex Medical Group (AIM:DEMG) ,a UK medical technology company, marketing a proprietary, minimally invasive real-time haemodynamic monitoring …

READ MORE
READ MORE NEWS & EVENTS

TWEETS

$ASC ASOS, biggest Co on AIM, written up as a Buy in @FinancialTimes FT Money section

Write up for Mark Slater’s Growth fund in @dailytelegraph Money section. $HCM Hutch Chi Med is 10.3% of this fund.

Final ED Forum of the year @HudsonSandler Wed 29 Nov: Impax, Destiny Pharma, Premier Tech. Popular already, book now https://t.co/55ebHTWfTN

$ERGO.L @ErgomedPLC new ED research out on recent deal, and newsflow ahead of expected PeproStat data. Free here: https://t.co/nALqek7NUq

UK shares to edge higher , despite Catalonian tension....which is as of yet not hurting the € ( 0.9014 v £ , 1.182 v $) .

$VAST.L full initiation research note just published by Phil Swinfen at ED. Free access here: https://t.co/ts07lKbRvl

FOLLOW US ON TWITTER

WHY CHOOSE ED

"I am delighted to go on record that Equity Development has done a very thorough and effective job for us in the last 9 months. In that period our share price has nearly doubled, and ED has published 7 notes to explain our results, acquisitions and key announcements. It has been very useful to stimulate interest amongst private investors, many of whom I have also enjoyed meeting. The timely and incisive notes have also gone down well with institutions. Last, and by no means least, ED’s willingness to work as part of a team alongside my Broker and PR firm has meant that this is a very simple relationship to manage."

Adrian Gunn
Matchtech

MORE REASONS

"From early days as a private company through to being established on AIM, I have always been able to rely on ED for wise counsel, perceptive research and introductions to new, supportive shareholders."

Arnab Basu
Kromek

MORE REASONS

"Many thanks to @equity_research for a superb Investor Forum. $BMK.L , $VLG.L & $VP.L all interesting companies. I recommend these events. "

Private Investor

MORE REASONS

"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."

Reg Hoare
MHP Communications

MORE REASONS